The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...

A research team has discovered an enhanced CRISPR gene-editing system that could enable targeted delivery inside the human ...

I am deeply humbled by the decades of support from people around the world. It is an honor to share this painful yet ...

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best healthcare penny stocks to buy according to hedge funds. On April 6, Canaccord reiterated its Buy rating on Taysha Gene Therapies Inc.

The ACC has published a scientific statement regarding the use of gene editing therapy for cardiovascular disease.

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. The Centers for Medicare and Medicaid Services announced in July ...

Current gene therapies to treat sickle cell disease are complex, time-consuming, and are sometimes linked to serious side effects like infertility or blood cancer. To address these challenges, Johns ...

Since 2017, a personalized immunotherapy called Chimeric Antigen Receptor, or CAR-T cell treatment, has worked wonders to ...

A new study has answered a question that has puzzled cancer researchers for decades: Does a genetic defect found in nearly ...

He said U.S. losses alone top $500 billion a year and called gene drives “the only scalable” solution. As reported by 24/7 ...